NAUT NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference

Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference

SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference.

Nautilus’ management is scheduled to present on Wednesday, March 25, 2026, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the company website at: .

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .

Media Contact

Investor Contact



EN
24/03/2026

Underlying

NAUTNAUTILUS BIOTECHNOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NAUTILUS BIOTECHNOLOGY INC

 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Participate in the Investor Summit Group Vir...

Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference. Nautilus’ management is scheduled to present on Wednesday, March 25, 2026, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the...

March 24, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Announces Baylor College of Medicine as First E...

Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform • Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit• NIH-funded project leverages collaborators’ expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analy...

March 18, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Fau...

Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to...

March 2, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Fin...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau da...

February 26, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molec...

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 • Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability Nautilus Voyager™ Platform ...

February 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch